Hua Li1, Qilu She1, Yu Liu2, Yuehe Ding1, Shenghua Shi1, Jijie Li1, Hongkai Wu3, Zhanhui Wang4. 1. Department of Infectious Diseases, Qinghai Provincial Infectious Diseases Hospital, Xining, China. 2. Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China. 3. State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. 4. Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China. w851419@yahoo.com.
Abstract
BACKGROUND AND AIM: Hepatitis B virus (HBV) C/D recombinant is predominant in Tibet in Western China. Although the geographical and ethnic distributions of the C/D recombinant have been described, the clinical implication and the characteristics of viral mutation in the basal core promoter (BCP)/pre-core (PC) region remain unclear. METHODS: A total of 174 chronic HBV carriers, including 115 with chronic hepatitis B, 45 with liver cirrhosis, and 14 with hepatocellular carcinoma, were enrolled. Using next-generation sequencing, the S and BCP/PC genes were determined and analyzed. RESULTS: Genotypes B, C2, D, and C/D recombinant were detected in 1.1% (2/174), 19.5% (34/174), 0.6% (1/174) and 78.7% (137/174) of the patients, respectively. The clinical parameters and viral mutation frequency in the BCP/PC region were compared between C2- and C/D recombinant-infected patients. The distribution of C2 and C/D did not differ by disease status or liver function. Significantly higher levels of HBV DNA (6.7 ± 1.6 vs. 5.9 ± 1.5, p = 0.014), HBeAg (263.5 vs. 20.0, p = 0.013) and A1762T/G1764A double-mutations (81.0 vs. 61.8%, p = 0.018), but a lower frequency of G1896A stop mutation (33.6 vs. 76.5%, p < 0.001) was observed in patients with the C/D recombinant than in patients with genotype C2. The clonal frequencies of A1762T, G1764A, G1896A and A1846T were lower in patients with C/D than C2. CONCLUSION: The C/D recombinant has different mutation pattern in the BCP/PC region compared with genotype C2. The lower clonal frequencies of BCP/PC mutations may explain the higher levels of HBV DNA and HBeAg in C/D-infected patients.
BACKGROUND AND AIM: Hepatitis B virus (HBV) C/D recombinant is predominant in Tibet in Western China. Although the geographical and ethnic distributions of the C/D recombinant have been described, the clinical implication and the characteristics of viral mutation in the basal core promoter (BCP)/pre-core (PC) region remain unclear. METHODS: A total of 174 chronic HBV carriers, including 115 with chronic hepatitis B, 45 with liver cirrhosis, and 14 with hepatocellular carcinoma, were enrolled. Using next-generation sequencing, the S and BCP/PC genes were determined and analyzed. RESULTS: Genotypes B, C2, D, and C/D recombinant were detected in 1.1% (2/174), 19.5% (34/174), 0.6% (1/174) and 78.7% (137/174) of the patients, respectively. The clinical parameters and viral mutation frequency in the BCP/PC region were compared between C2- and C/D recombinant-infected patients. The distribution of C2 and C/D did not differ by disease status or liver function. Significantly higher levels of HBV DNA (6.7 ± 1.6 vs. 5.9 ± 1.5, p = 0.014), HBeAg (263.5 vs. 20.0, p = 0.013) and A1762T/G1764A double-mutations (81.0 vs. 61.8%, p = 0.018), but a lower frequency of G1896A stop mutation (33.6 vs. 76.5%, p < 0.001) was observed in patients with the C/D recombinant than in patients with genotype C2. The clonal frequencies of A1762T, G1764A, G1896A and A1846T were lower in patients with C/D than C2. CONCLUSION: The C/D recombinant has different mutation pattern in the BCP/PC region compared with genotype C2. The lower clonal frequencies of BCP/PC mutations may explain the higher levels of HBV DNA and HBeAg in C/D-infected patients.
Entities:
Keywords:
C/D recombinant; Genotype; Hepatitis B virus; Mutation
Authors: G Zeng; Z Wang; S Wen; J Jiang; L Wang; J Cheng; D Tan; F Xiao; S Ma; W Li; K Luo; N V Naoumov; J Hou Journal: J Viral Hepat Date: 2005-11 Impact factor: 3.728
Authors: Julianne Bayliss; Lilly Yuen; Gillian Rosenberg; Darren Wong; Margaret Littlejohn; Kathleen Jackson; Anuj Gaggar; Kathryn M Kitrinos; G Mani Subramanian; Patrick Marcellin; Maria Buti; Harry L A Janssen; Ed Gane; Vitina Sozzi; Danni Colledge; Rachel Hammond; Rosalind Edwards; Stephen Locarnini; Alexander Thompson; Peter A Revill Journal: Gut Date: 2016-08-17 Impact factor: 23.059
Authors: A Pivert; A Servant-Delmas; F Lunel-Fabiani; H Le Guillou-Guillemette; S Laperche; A Ducancelle Journal: J Med Virol Date: 2014-08-29 Impact factor: 2.327